Previous Chapter Chapter 26: Outlook for Cancer Vaccine Development Next Chapter

By: Decision Resources Inc

In: The SAGE Handbook of Healthcare

Chapter 26: Outlook for Cancer Vaccine Development

  • Citations
  • Add to My List
  • Text Size

Outlook for Cancer Vaccine Development
Outlook for cancer vaccine development
An Era of Change for Cancer Therapy

With the rapid incorporation of monoclonal antibodies (MAbs) into oncology therapy, an environment of acceptance of new biologic therapies – including cancer vaccines – as a viable therapeutic approach is forming. Genentech and ImClone's highly visible and successful 2004 MAb launches (bevacizumab [Avastin] and cetuximab [Erbitux], respectively) have increased anticipation for the next new therapy. Although Dendreon's long-awaited cancer vaccine, Provenge, has not yet delivered on earlier expectations, several vaccines, specifically Merck's Gardasil and GlaxoSmithKline's Cervarix, are rapidly approaching their filing dates and have the potential to initiate the therapeutic acceptance of cancer vaccines.

The gold standard for cancer treatment remains chemotherapy, but combination therapy, particularly combining chemotherapy agents with biologies, ...

Looks like you do not have access to this content.


Don’t know how to login?

Click here for free trial login.

Back to Top

Copy and paste the following HTML into your website